CONFIDENTIAL Protocol 2034-201-[ADDRESS_1170544] -T-01-01 v2.0
Title Page
Protocol Title : A Phase 2b Double -Blind, Placebo -Controlled, Dose- Ranging Study  to Evaluate 
the Safety and Efficacy of AGN -151586 in Participants With Moderate to Severe Glabellar Lines
Protocol Number: 2034-201-008
Amendment Number:  [ADDRESS_1170545]: AGN -151586 (Botulinum Neurotoxin Seroty pe E, BoNT/E) for injection
Brief Protocol Title: AGN -151586 Dose -Ranging Study  for Treatment of Glabellar Lines
Development Phase: 2b
Sponsor Name :[CONTACT_842345]: Allergan Sales LLC
5 Giralda Farms
Madison, NJ 07940[LOCATION_003]
Regulatory Agency Identifying Number: IND Number 130880
Emergency Telephone Number Refer to the stud y contacts page
SAE Reporting Fax Number/Email:
Business Unit 
/Legacy 
Organization Email Phone Fax
Allergan IR-Clini [EMAIL_15966] Not applicable +1 -[PHONE_3451] 
Backup: 
+[PHONE_1851]
Sponsor Signatory:
Vice President , Head of Clinical Development, Aesthetic Medicine
Refer to the final page of this protocol for electron icsignature [CONTACT_51472].
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-008 Final 1[STUDY_ID_REMOVED]
CONFIDENTIAL Protocol 2034-201-[ADDRESS_1170546] -T-01-01 v2.0
Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment 1 June 2020
Original Protocol July 2019
Amendment 1 (June 2020)
Overall Rationale for the Amendment:
The primary purpose of this p rotocol amendment i s to update study  processes related to the 
analysis of immunogenicity  samples for optional exploratory  research and improve clarit y of 
study  processes as summarized below.
Section No. and Name [CONTACT_842346] P age Updated sponsor signatory’s title Update
8.2.5/Electrocardiograms Added statement that exclusion alerts based 
on prespecified significant abnormal 
electrocardiogram findings are considered 
exclusionary for study eligibility (consistent 
with exclusion criteria in Section 5.2).Improve clarity
8.8/Biomarkers and Other 
AssessmentsAdded statement sthat immunogenicity 
samples may be used for additional 
characterization of antibody response to other neurotoxin subtype(s) and described 
the informed consent process for this 
optional exploratory research.Update
[IP_ADDRESS]/Immunogenicity AnalysesAdded statement that additional immunogenicity exploratory analyses may be performed.Update
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170547] of Figures.................................................................................................................................61. Protocol Summary ..........................................................................................................7
1.1. Synopsis ............................................................................................................................7
1.2. Schema............................................................................................................................10
1.3. Schedule of Activities (SoA) ..........................................................................................[ADDRESS_1170548] ion...................................................................................................................15
2.1. Study  Rationale ...............................................................................................................15
2.2. Background .....................................................................................................................15
2.3. Benef it/Risk Assessm ent................................................................................................17
3. Objectives and Endpoints ............................................................................................19
4. Study Design..................................................................................................................20
4.1. Overall D esign ................................................................................................................20
4.1.1. Clinica l Hypotheses ........................................................................................................21
4.2. Scientific Rationale for Study  Design ............................................................................21
4.3. Justification for Dose......................................................................................................22
4.4. End of Study Definition ..................................................................................................24
5. Study Population...........................................................................................................25
5.1. Inclusion Criteria ............................................................................................................25
5.2. Exclusion Criteria ...........................................................................................................27
5.3. Lifesty le Considerations .................................................................................................29
5.4. Screen Failures ................................................................................................................29
6. Study Intervention ........................................................................................................306.1. Study  Interventions Administered ..................................................................................30
6.1.1. Study  Supplies ................................................................................................................30
6.1.2. Instructions for Use and Administration .........................................................................32
6.2. Preparation/Handling/Storage/Accountability................................................................32
6.3. Measures to Minimize Bias: Randomization and Blinding............................................336.4. Study  Intervention Compliance ......................................................................................34
6.5. Concomitant Therapy .....................................................................................................346.5.1. Prohibited Interventions ..................................................................................................34
6.5.2. Per mitted I nterventions ...................................................................................................35
6.5.3. Rescue Medicine .............................................................................................................35
6.6. Dose Modification ..........................................................................................................35
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170549] -T-01-01 v2.0
9.4.1. E fficacy  Anal yses...........................................................................................................50
9.4.2. Safety Anal yses...............................................................................................................51
9.4.3. Other Anal yses................................................................................................................52
9.5. Interim Anal yses.............................................................................................................53
10. Supporting Documentat ion and Operational Considerations..................................54
10.1. Appendix 1: Regulatory , Ethical, and Study Oversight 
Considerations ................................................................................................................55
10.1.1. Regulatory  and Ethical Considerations...........................................................................55
10.1.2. Financial Disclosure........................................................................................................55
10.1.3. Informed Consent Process ..............................................................................................55
10.1.4. Data Protection................................................................................................................5610.1.5. Posting Clinical Study  Data ............................................................................................56
10.1.6. Data Qualit y Assurance ..................................................................................................56
10.1.7. Source Documents ..........................................................................................................5710.1.8. Study  and Site Clo sure....................................................................................................57
10.1.9. Publication Policy ...........................................................................................................58
10.1.10. Compliance with Protocol...............................................................................................5810.2. Appendix 2: Clinical L aboratory  Tests...........................................................................59
10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting.........................................................60
10.4. Appendix 4: Abbreviations.............................................................................................6510.5. Appendix 5: Standard Discontinuation Criteria..............................................................6710.6. Appendix 6: Study  Tabular Summary ............................................................................69
10.7. Appendix 7: Contraceptive Guidance and Collection of 
Pregnancy  Information ...............................71...............................[ADDRESS_1170550] of Tables
Table 4-1 AGN- 151586 Completed Clinical Studies ............................................................ 23
Table 10-1 Protocol- Required Safet y Laboratory  Assessmentsa............................................ 59
Table 10-2 Highl y Effective Contraceptive Methods ............................................................. 72
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170551] of Figu res
Figure 6–1 (A) The Procerus and Corrugator (Glabellar Line Area) on 1 Side of the Face and 
(B) Locations of the 5 Glabellar Line Injections .................................................. 32
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170552] -T-01-01 v2.0
1. Protocol Summary
1.1. Syn opsis
Protocol Title: A Phase 2b Double -Blind, Placebo -Controlled, Dose- Ranging Study  to Evaluate 
the Safet y and Efficacy  of AGN-151586 in Participants With Moderate to Severe Glabellar Lines
Protocol Number: 2034-201-008
Amendment Number: 1 
Brief Title: AGN- 151586 Dose -Ranging Study  for Treatment of Glabellar Lines
Study Phase: 2b
Study Rationale:
The purpos e of this Phase 2b study  is to evaluate the safet y and efficacy  of AGN-151586 over a 
range of doses for the treatment of moderate to severe glabellar lines (GL) .
Objectives and Endpoints:
Objectives Endpoints
Primary
Efficacy: To compare the efficacy be tween placebo 
and a range of doses of AGN -151586 for the 
treatment of GL in participants with moderate to 
severe GL
Safety: To compare the safety bet ween placebo and 
a range of doses of AGN -151586 for the treatment 
of GL in participants with moderate to se vere GLAchievement of a ≥ 2-grade improvement from 
baseline on the Facial Wrinkle Scale With 
Photonumeric Guide (FW S) according to 
investigator assessments of GL severity at 
maximum frown at any postintervention timepointthrough Day 7 .
Incidence of adverse events; change from baseline 
in hematology/chemistry /urinalysis laboratory, 
vital sign,and electrocardiogram (ECG) 
parameters; and presence of antidrug antibodies
Overall Study Design :
This is a multicenter, double-blind, randomized, placebo-controll ed, dose-escalation 
study toevaluate the safety  and efficacy  of a single study  intervention cycle of 
AGN-151586 in participants with moderate to sev ere GL.  
Participants are adults 18 to 65 y ears old, with moderate to severe GL at maximum frown 
(as asses sed by [CONTACT_842324] ).
Up to [ADDRESS_1170553] dose.  
Each cohort will enroll a balanced distribution of participants with moderate or s evere 
GL severit y at maximum frown per investigator assessment (at least 40% and no more 
than 60% of either ).
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170554] -T-01-01 v2.0
The primary  efficacy  measure is the investigator’s assessments of GL at maximum frown 
using the FWS.
Participants will undergo a Screening Visit up to 30days before randomization on Day 1. 
All screening data must be available tothe investigator prior to randomization on Day  1.
On Day  1, participants will be randomly  assigned in a 3:1 ratio to receive AGN-151586 
or placebo. Enrollment stratificat ion will be by  [CONTACT_842325], 
assessed by [CONTACT_15370] ( principal investigator [INVESTIGATOR_842317]) using the
FWS. 
Study  intervention on Day 1 will be administered as 5 injections in the glabellar complex 
(1 in the proce rus and 2 in each corrugator).
Participants will remain in the clinic for the first 12 hours after admi nistration of study  
intervention for serial as sessments at Hours 4, 8 and 12. Thereafter, participants return to 
the clinic on Day  2 (Hour 24 and Hour 36 ),Day 3 (Hour 48 and Hour 60) , Day 7, 
Day 14, Day 21, Day 28, Day 35, and Day 42.  
For each dose group, an internal data monitoring c ommittee (DMC ), independent from 
the study  team ,will review select safety and efficacy data from a subset of participant s 
(n≥16) with data through 14 days postintervention (in addition to cumulative data from 
the prior cohort[s]) .
The DMC may  recommend proceeding with the nominal dose for the next cohort, request 
additional data (eg, data from additional participants in the cohort, data from visits after 
Day 14), request to repeat the current dose or a lower dose, requ est an intermediate dose 
be evaluated (between the dose of the current cohort and the nominal dose for the next 
cohort), or request dose escalation be termin ated.
Number of Participant s:
Approximately  200 participants will be enrolled. Accounting for a dropout rate of 10%, it is 
anticipated that approxima tely 180 participants will complete the study .A total of up to 5 dose 
cohorts are planned with a randomiza tion allocation of 3:1 for AGN-151586 (n = 30) a nd 
placebo (n = 10) for each cohort.
Number of Sites:
Approximately  10 US investigational sites
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170555] -T-01-01 v2.0
Inter vention Groups and Study Duration:
The total duration of study participation for each participant is up to ap proximately  72days. 
Participants will attend the following visits:
Screening (up to 30 days before randomization)
Day 1
oHour 0 (r andomization and administration of study  interventio n)
oHour 4
oHour 8
oHour 12
Follow- up visits:
oDay 2,Hour 24
oDay 2, Hour 36
oDay3, Hour 48
oDay 3, Hour 60
oWeekly  (Days 7, 14, 21, 28, and 35)
Exit (Day 42) 
Data Monitoring Committee: Yes
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170556] -T-01-01 v2.0
Visit Number 1 2 3456789 10 11 12
Study PeriodScreening 
(Days −30
to −1)Randomization
and Study
Intervention 
(Day 1)aDay 1bFollow -upEnd of 
Study
(Day 42 
or 
Early 
Exit) Day 2 Day 3Day 
7Day 
14Day 
21Day 
28Day 
35
Time after 
administration of 
study intervention -- -- 4 h 8h 12h 24h 36h 48 h 60 h
Visit windows -- -- ±1 h ±1h ±1h ±2h ±2h ±2h ±2h±1 
day±1 
day±1 
day±1 
day±1 
day ±1 day
Collection of blood 
samples for 
immunogenicity 
testingX X X X
Adverse events X XjXXXXXXXXXXXX X
Concomitant 
medicationsX X XXXXXXXXXXXX X
Concurrent proceduresX X XXXXXXXXXXXX X
Study intervention administrationX(0 h)
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170557] -T-01-01 v2.0
ECG = electrocardiogram; ; 
GL = glabellar lines; WOCBP = women of childbearing potential
aAll makeup must be removed and hair not obscuring the upper face prio r to completing any assessment. All assessments must be completed before administration of study 
intervention at Hour [ADDRESS_1170558] remain at the investigational site on Day 1 (ie, from baseline procedures through Hour 12 assessment).
cThe invest igator and participant must grade the severity of GL using the FWS at the same time, first at rest, then at maximum frown. The investigator and participant must not 
discuss their results with each other. 
dA complete physical examination is to be done at the Screening Visit and EOS/Early Exit Visit. A n abbreviated physical examination isto be done at other visits . The 
abbreviated physical examination islimited to an examination of general appearance, heart, lungs, and abdomen.
eVital sign measurements inc ludes pulse rate, respi[INVESTIGATOR_1487], blood pressure, and body temperature. Participants are to be seated for at least 2 minutes before measurements 
arecollected.
fThe n eurologic assessment includes the Focused Symptom Questionnaire and Focused Neurologi c Examination. 
gWomen of childbearing potential (WOCBP) must have a negative pregnancy test at the Screening Visit and on Day [ADDRESS_1170559] discuss with WOCBP and 
males with partners who are WOCBP complian ce with contraceptive use.
hA 12 -lead ECG will be taken with the participant in a semirecumbent position for ≥ [ADDRESS_1170560] 30minutes after study intervention for adverse events.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170561] serot ypes of botulinum 
neurotoxins designated A through G ( Barash 2014; Keller 2006) . These neurotoxins are some of 
the most potent molecules in nature, and all have the capability  to block skeletal muscle 
contraction b y blocking presynaptic acet ylcholine release at the neuromuscular nerve junction.
Even though they have similar modes of action, each serot ype has distinct properties that 
differentiate them from each other. 
Botulinum N eurotoxin Seroty pe E has been shown to inhibit muscle contraction by [CONTACT_842326]. This effect has been shown in animals as 
well as humans ( Adler 2001 ; Eleopra 1998). Epi[INVESTIGATOR_842318]/E have shown classic signs of s ystemic disease 
characterized b y flaccid paral ysis with earlier onset than classic botulism with BoNT/A 
(McLaughlin 2004 ).
In the published literature, BoNT/E has a distinct profile with a faster onset and shorter duration 
of effect compared with BoNT/A. N onclinical studies have shown BoNT /E to have faster 
translocation in neurons ( Keller 2004) and faste r inhibition on neuromuscular transmission
(Wang 2008), suggesting its potential effect of faster onset of action in comparison with 
BoNT/A . A clinical trial in humans showed that participants recovered faster from paral ysis after 
BoNT/E was injected into extensor digitorum b revis muscles, suggesting its duration of 
conferring paralytic effect might be shorter than BoNT/A (Eleopra 1998). 
Indication
Glabellar lines are deep furrows or frown lines in the glabellar area of the face andresult from 
the repetitive functional action of the underly ing mimetic facial musculature during animation 
(Blitzer 1993). The development of facial lines (such as GL) is an age-related change of the face 
that occurs be cause of the repetitive muscle contractions that a reassociated with common facial 
expressions. Thus, these facial lines can be observed with contraction (d ynamic rh ytides) or in 
more severe cases in repose (static rh ytides). Increasing severit y in the app earance of facial lines 
has been associated with a patient’s perception of reduced attractiveness and a negative effect on 
self-esteem and sense of well-being ( Koblenzer 1996 ). Furthermore, the appearance of these 
facial lines can lead to a miscommunication of an emotional st ate of anger, anxiety , disapproval, 
or sadness ( Khan 2001), causing distress and affecting social interactions ( Finn 2003).
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170562] -T-01-01 v2.0
Evidence supports that unattractive or aging skin is indeed related to p sychological and 
psychosocial impacts ( Farage 2010). Psychological or psy chosocial impacts can be characterized 
as changes in confidence, attractiveness, self- esteem, emotional burdensomeness, self-
perceptions of appearance or age, emotional distress, and state of bother. The evaluation of 
psychological or psychosocial impacts associated with aging facial skin should be assessed from 
patients’ perspectives since these impacts are dependent on their perceptions.
The popularit y of BoNT /A cosmetic treatment of GL in adul ts is related to its proven efficacy  for 
reducing moderate to severe facial lines ( Beer 2006); well documented safety profile
(Brin 2009); and positive imp act on psy chological well-being and the r esulting ps ychosocial 
benefits ( Finn 2003).
When injected at therapeutic doses, it is expected that BoNT/E, like BoNT/A, produces parti al 
chemical denervation of the muscle, resulting in localized reduction in muscle activity. Because 
GL result from muscular activity , the muscle relaxation leads to a temporary  relief of facial lines. 
While it was previously  thought that these facial lines were structural and permanent, the effects 
of the seinjections demonstrate the lines are part functional and may  be associated with persistent 
increased muscle tone ( Garcia 1996; Le Louarn 2007 ).
Based on published data for B oNT/E, in addition to preclinical and clinical exper ience swith 
AGN-151586, it is anticipated that at a clinically efficacious dose, AGN- 151586 will exhibit a 
faster onset of improvement in GL severit y compared with BoNT/A, with shorter duration of 
treatment effect.
AGN-151586
AGN-151586 (previously  refer red to a s EB-001) is a BoNT/E and has been evaluated in clinical 
studies for various indications up to a total dose of U. These studies are briefl y summarized 
below. For additional information and details, please refer to the IB.
The first -in-human stud y (EB001-GL201 ) determined that over a limited range of doses up to 
U, AGN -151586 waswell tolerated when injected in the glabellar complex (procerus and 
bilateral corrugator muscles) and exhibited a trend of fastonset (within 24 hours) and a limite d
duration of clinical effect ( approximately  2 weeks) compared with the well characterized clinical 
profile of BoNT/A for the treatment of GL . 
In a Phase 2 exploratory  study  (EB001- SR201 ), a single dose of U AGN -151586 was 
administered as 5 injections (divided equall y) to the frontalis muscle during Mohs surgery  in the 
forehead. The data suggested favorable safety  and tolerability at the tested dose. During the 
wound healing and acute scar formation pha se (up to Day 30),descriptive results of some of th e 
exploratory  anal yses were consistent with the hy potheses thatAGN- [ADDRESS_1170563] been sufficient to capture the optimal efficacy response for 
postsurgical scar reduction. The safet y and efficacy  of AGN -151586 injections in reducing postsurgical musculoskeletal pain 
in particip ants undergoing elective augmentation mammoplasty  wasevaluated in 
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170564] -T-01-01 v2.0
Study EB001 -MA201. Six doses of AGN-151586 ( ranging from U)were 
evaluated. No dose response was observed, and there was no st atistically  significant difference in 
pain reducti on between any dose group compared with placebo. This study  showed favorable 
safet y and tolerability.
The safet y and efficacy of AGN-[ADDRESS_1170565] when 
compared with BoNT/A in these animal models, it is also less potent in terms of extent of muscle 
paral ysis at peak efficacy. The magnitude of lower potency of BoNT/E compared with BoNT/A 
is varied, depending on the species and on the assay s (Dona ld 2018). Higher doses may  be 
needed to achieve d emonstrable therapeutic responses.
For additional information , please refer to the IB.
2.3. Benefit/Risk  Assessment
Generally , the popularity of BoNT/A cosmetic treatment of GL in adults is related to its proven
efficacy  for reducing moderate to severe facial l ines(Beer 2006 );well documented safet yprofile
(Brin 2009); and positive impact on psychological well-being and the resulting ps ychosocial 
benef its (Finn 2003). Compared with the general class of BoNT/A treatments, AGN-[ADDRESS_1170566] and requires 
no reconstitution. Secondly, it offers the potential for faster onset of efficacy compared with the 
BoNT/A products.
Four controlled, P hase [ADDRESS_1170567] received a single study  intervention cycle of AGN -151586 (highest ex posure 
was U,and [ADDRESS_1170568] receiv edplacebo (identical to AGN- 151586 but without 
toxin) . Of those who received AGN -151586, h eadache ( n=2), vital capacity decreased ( n=2), 
pruritus/pruritus generalized (n = 2), and nausea ( n=1) were t he onl y adverse events considered 
treatment -relate d by [CONTACT_093]. These adverse events were mild to moderate in severit y and 
resolved. The adverse event profile associated with AGN-151586 showed no unusual findings; 
no safety signal was identified.
The relevant anatom y and any alterations to the a natomy  due to prior surgical procedures must 
be understood prior to administering AGN -151586 , and care should be taken when injecting in 
or near vulnerable anatomic structures. Caution should also be exercised when AGN -151586 is 
used in the presence of inf lammation at the proposed injection site(s) or when excessive 
weakness or atroph y is present in the target muscle. As is expected for an y injection procedure, 
localized pain, inflammation, paresthesia, h ypoesthesia, tenderness, swelling/edema, ery thema, 
localized infection, bleeding, and/or bruising may be associated with the injection of 
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170569] -T-01-01 v2.0
AGN-151586 or placebo. Needle- related pain and/or anxiety  could result in vasovagal responses, 
including transient s ymptomatic hypotension and sy ncope.
In some cases, botu linum toxin effect may be observed bey ond the site of local injection. The 
symptoms are consistent with the mechanism of action of botulinum toxin and may include 
asthenia, generalized muscle weakness, diplopia, ptosis, dy sphagia, dy sphonia, dy sarthria, 
urinary retention , and breathing difficulties. These symptoms have been reported hours to week s 
after injection. Swallowing and breathing difficulties can be life threatening, and there have been 
reports of death related to spread of toxin effects. The risk of symptoms is probably greatest in 
children treated for spasticity, but s ymptoms can also occur in adults treated for spasticity  and 
other conditions, and particularly in those patients who have an underly ing condition that would 
predispose them to these sy mptoms.
Reduced blinking has been reported after BoNT/A product injection to the orbicular is muscle , 
andcan lead to corneal exposure, persistent epi[INVESTIGATOR_17754], and corneal ulceration with 
perforation. For treatment of blepharospasm using a BoNT/A pr oduct , corneal perforation in an 
aphakic ey e requiring corneal grafting has occurred because of this effect. Although these effects 
mentioned above have not been reported for BoNT/E, these may be anticipated because the mechanism of action of BoNT/E is similar to BoNT/A.
In addition to investigator and the sponsor’s MSP oversight, a DMC has been instituted to 
provide oversight in this study . The dose -escalation design of this study  allows for careful review 
of select safet y and efficacy data by [CONTACT_842327]/benefit assessments prior 
to escalation to the next higher dose. The DM C may  recommend proceeding with the nominal 
dose for the next cohort, request additional data, request to repeat the current dose or a lower 
dose, request an interm ediate dose be evaluated (between the dose of the current cohort and the 
nominal dose for the next cohort), or request dose escalation be terminated.
More detailed information about the known and expected benefits and risks, reasonabl y expected 
adverse even ts of AGN -151586 , and measures to control the serisks can be found in the IB.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170570] -T-01-01 v2.0
3. Objectives and Endpoints
Objectives Endpoints
Primary
Efficacy: To compare the efficacy betw een placebo 
and a range of dose s of AGN -151586 for the 
treatment of GL in partic ipants with moderate to 
severe GL
Safety: To com pare the safety betw een placebo and 
a range of doses of AGN -151586 for the treatment 
of GL in participants with moderate to severe GLAchievement of a ≥ 2-grad e improvement from 
baseline on the FWS according to investigator 
assessments of GL severity at maximum frown at any postintervention timepoint through Day 7 .
Incidence of adverse events; change from baseline 
in hematology/chemistry/urinalysis labor atory, 
vital sign ,and ECG parameters; and presence of
antidrug antibodies
Nonprimary assessments are specified in the SAP and COA SAP.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170571] -T-01-01 v2.0
4. Study Design
4.1. Overall Design
This is a multicenter, double-blind, randomized, placebo-controlled, dose-escalation 
study toevaluate the safety  and efficacy  of a single study  intervention cycle of 
AGN-151586 in participants with moderate to severe GL.  
Participants are adults 18 to 65 y ears old, with moderate to severe GL at maximum frown 
(as assessed by [CONTACT_842324]).
Up to [ADDRESS_1170572] dose.
Each cohort will enroll a balanced distribution of participants with moderate or severe GL severit y at maxi mum frown per investigator assessment (at least 40% and no more 
than 60% of either ).
The primary  efficacy  measure is the investigator’s assessments of GL at maximum frown 
using the FWS.
Participants will undergo a Screening Visit up to [ADDRESS_1170573] be available to the investigator prior to randomization on Day  1.
On Day  1, participants will be randomly  assigned in a 3:1 ratio to receive AGN-151586 
or placebo. Enrollment stratification will be b y baseline GL severity at maximum frown, 
assessed by [CONTACT_15370] (pri ncipal investigator or physician subinvestigator) us ing the
FWS.  
Study  intervention on Day 1 will be administered as 5 injections in the glabellar complex 
(1 in the procerus and 2 in each corrugato r).
Participants will attend the following visits:
oScreen ing (up to 30 days before randomization)
oDay 1
Hour 0 (r andomization and administration of study intervention)
Hour 4
Hour 8
Hour 12
oFollow- up visits:
Day 2,Hour 24
Day 2, Hour 36
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170574] -T-01-01 v2.0
Day 3, Hour 48
Day 3, Hour 60
Weekly  (Days 7, 14, 21, 28, and 35)
oExit (Day 42)
Participants will remain in the clinic for the first [ADDRESS_1170575] completed the Day 14 visit. Following 
this review, the DMC will determine whether the study  will proceed to Cohort 2 of dose 
escalation. After Cohort 2 proceeds, a similar review proces s will occur to determine whether 
Cohort 3 will proceed . This pattern repeats prior to the start of each new cohort. At each DMC 
review, data through Day 14 from a subset of participants (n≥ 16) for an y given cohort will be 
reviewed. Additionally , cumulat ive data from participants from the prior cohort(s) will also be 
included in the DMC review.  
At each DMC review, the DMC may recommend proceeding with the nominal dose for the next 
cohort, request additional data (eg, data from additional participants in the coh ort, data from 
visits after Day  14), request to repeat the current dose or a lower dose, request an intermediate 
dose be evaluated (between the dose of the current cohort and the nom inal dose for the next 
cohort), or request dose escalation be terminated. 
The dose-escalation design of this study  allows for careful review of select safety and efficacy 
data by [CONTACT_842328]/benefit prior to escalation to the next higher dose. Details of the 
activities and composition of the DMC are further describe d in the DMC charter.
4.1.1. Clinical Hypoth eses
Efficacy: A single study  intervention cycle of AGN -151586 within the dose range evaluated is 
more effective than placebo in the treatment of GL, measured b y investigators’ assessments of 
GL severit y at maxi mum frown using the FWS.
Safety : A single study  intervention cycle of AGN -151586 has an acceptable safety profile at the 
doses evaluated. 
4.2. Scientific Rationale for Study Design
AGN-151586 isa BoNT/E product being developed for IM injections in the treatme nt of GL . 
Currently , this indica tion is commonly treated with BoNT/A products. AGN -[ADDRESS_1170576] . This 
study  is designed to evaluate the tolerabilit y and ef ficacy  profiles of AGN-151586 for the 
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170577] y:
1. Age
1.[ADDRESS_1170578] be 18 to 65 years of age inclusive, at the time of sign ing the informed 
consent .
2. Type of Participant and Characteristics
2.01 Moderate to severe GL at maximum frown ( as assessed by [CONTACT_842329] ) at Screening and on Day  [ADDRESS_1170579] sufficient visual acuit y without the use of ey eglasses (contact 
[CONTACT_591114]) to accurately assess their facial lines, in the opi[INVESTIGATOR_1070].
3. Sex
3.01 Male or female
4. Contraceptives
4.01 Female participants willing to minimize the risk of inducing pregnancy  for the duration 
of the clinical stud y and follow -up period (at least 10 weeks after study  interventio n)
4.02 A female participant is eligible to participate if she is 1) not a WOCBP*, or 2) a 
WOCBP who is not pregnant (ie, has a negative pregnancy test at the Screening Visit 
and prior to randomization; see Appendix 7), is not breastfeeding, is not planning a 
pregnancy during the study , and a grees to follow the contraceptive guidance in 
Appendix [ADDRESS_1170580] 4 weeks after study  completion (at least 
10weeks after administration of study  intervention ).
*A woman is considered NOT to be of childbearing potential if she is premenarchal, pos tmenopausal (at 
least 12 consecutive months of amenorrhea), or surgically sterilized (eg, hysterectomy or bilateral 
oophorectomy).
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170581] 6 weeks after administration of study  intervention: 
Are abstinent from penile-vaginal intercourse as their usual and preferred lifesty le 
(abstinent on a long-term and persistent basis) and agree to remain abstinent
Agree to use a male condom with spermicide plus partner use of a contraceptive 
method with a failure rate of < 1% per year as described in Appendix [ADDRESS_1170582] 6 weeks after 
administration of study intervention.
5. Informe d Consent
5.01 Capable of giving signed informed consent as described in Appendix 1 , which includes 
compliance with the requirements and restri ctions listed in the I CF and this protocol
5.02 Written informed consent from the participant has been obtain ed prior to any  study -
related procedures 
5.03 Written documentation has been obtained in accordance with the relevant local privacy 
requirements , where applicable.
6. Other
6.01 Participants in good health as determined b y me dical history , phy sical examination , 
neurological assessment , clinical laboratory  evaluation s, ECG, vital signs, and 
investigator’s judgment
6.02 Ability  to follow study  instructions, including completing stu dy assessment tools 
without any assistance or a lteration to the assessment tools and likely to complete all 
required visits
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170583] -T-01-01 v2.0
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
1. Medical Conditions
1.01 Any condition that precludes a participant’s ability  to compl y with study requirements, 
including completion of the study  visits or inability to read, understand, and/or self -
assess GL severity using the FWS
1.02 Known immunization or hy persensitivity  to any botulinum neuro toxin seroty pe
1.03 Known alle rgy or sensitivity  to an y of the components of the study interventions or any  
materials used in the study  procedures
1.04 Any medical condition that may  put the participant at increased risk with exposure to 
AGN-151586, including diagnosed myasthenia grav is, Eaton- Lambert syndrome,
amyotrophic lateral sclerosis, or any  other condition that might interfere with 
neuromuscular function
1.05 Any history  of significant cardiovas cular disease, family  history  of long QT syndrome, 
or a clinically significant ECG abnormality at the Screenin g Visit
1.06 Marked facial as ymmetry , dermatochalasis, deep dermal scarring, exc essively  thick 
sebaceous skin, or the inability  to substantially  lessen facial lines even by  [CONTACT_55896] y 
spreading them apart, as determined b y the i nvestigator
1.07 Any brow or ey elid ptosis, as determined b y the investigator
1.08 Infection or skin disor der at the injection sites
1.09 History  of facial nerve palsy
1.10 Any uncontrolled s ystemic disease
1.11 Any medical condition that, in the opi[INVESTIGATOR_871], pu ts the participant at 
undue safet y risk
1.12 History  of alcohol or drug abuse within 3 months of randomization based on the 
investigator’s judgment
1.[ADDRESS_1170584] udy (other than study  intervention )
1.14 Anticipated need for surgery  or overnight hospi[INVESTIGATOR_842319]: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170585] -T-01-01 v2.0
2. Prior/Concomitant Therapy
2.[ADDRESS_1170586] 12
months prior to screening.
2.02 Any of the following procedures or treatments occurring in the specified period before 
randomization ( Day 1):
3 months: any  facial nonablative resurfacing laser, light or ultrasound treatment, 
microdermabrasion, monopolar radiofrequency , or superficial peels
6 months: any facial cosmetic procedure with medium depth or deep depth 
chemical peels (eg, TCA and phenol); periorbital, mid-facial, or upper-facial skin 
resurfacing; or permanent make-up in the mid-facial (extending from inferior 
orbital margin to level of the nasal base) or upper facial areas
12 months: any periorbital, mid -facial, or upper-facial treatment with 
nonpermane nt soft tissue fillers
2.03 Participants on topi[INVESTIGATOR_737172]/or topi[INVESTIGATOR_842320], who have not been on a consistent dose regimen for at least 6 months before randomization and who are unable to maintain the same regime n for the study
2.04 Participants on oral retinoid therap y within 1 year before stud y enrollment
2.05 Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid [blepharoplast y] and/or ey ebrow surgery )
2.06 Prior faci al treatment with permanent soft tissue fillers, synthetic implantation (eg, Gore-
Tex®), and/or autologous fat transplantation
3. Prior/Concurren t Clinical Study Experience
3.[ADDRESS_1170587] from the immediate area of the study  site that would preclude them from returning for all protocol- specified study visits
4.02 Participants who, in the investigator’s opi[INVESTIGATOR_1649], are unable or unwilling to maintain their standardized skin care regimen throughout the study  period
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170588] and administration of 
this study as a principal investigator, subinve stigator, study  coordinator, or other study  
staff member; or employee of the sponsor, or a first-degree family member, significant 
other, or relative residing with one of the above persons involved directl y or indirectl y in 
the study
4.05 The participant has a condition or is in a situation which, in the investigator’s opi[INVESTIGATOR_1649], 
may put the participant at signific ant risk, may confound the study results, or may  
interfere significantl y with participation in the study.
5.3. Lifestyle Considerations
No restrictions are required.
5.4. Screen Failures
Screen failures are defined as participants who con sent to participate in the clinical study but are 
not subsequently  randomly  assigned to study  intervention .
A minimal set of screen failure information is required to ensure transparent reporting of screen 
failure participants to meet the CONSORT publishing requirements and to respond to queries 
from regulatory  authorities. Minimal information includes indicating screen failure as reason for 
ending the stud y, demography, scr een failure details, eligibility criteria, and any  SAE .
Individuals who do not meet the eligibility  criteria f or participation in this study  (screen failures ) 
may be allowed to be rescreened. Rescreening of participants must only occur after discussion 
with the sponsor. Rescreened participants must be assigned new participant identifica tion 
numbers . Rescreening c an only  occur once for any given potential participant.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170589] -T-01-01 v2.0
6.1.2. Instructions for Use and Administration
Only  a qualified phy sician trained i n the study -specific inj ection technique may administer study  
intervention. 
Study  intervention is a dministere d as IM injections at 5 injection sites in the glabellar complex, 1 
in the procerus and 2 in each corrugator muscle ( Figure 6-1A).
Participants must be observed for adverse events for at least 30minutes after study interventio n 
injection.
6.2. Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have be en 
maintained during transit for all study intervention received and an y discrepancies are 
reporte d and resolved before use of the study  intervention .
2.Only  participants enrolled in the study  may  receive study  intervention, and only  authorized 
site staff may supply  or administer study  intervention .All study  intervention must be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff .
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170590] that specifies the amount of study 
intervention administered to each participant and the date of administration.
6.5. Concomitant Therapy
Concomitant therapy and/or medications considered necessa ry for the study participant’s welfare 
may be given at the discretion of the investigator.
The use of an y medication during the stud y(including prescription or over- the-counter
medication, vitamins, and/or herbal supplements) is to be recorded on the participant’s eCRF at 
each visit along with the reason the medication is taken, dates of use, and dosing regimen.
Study  site personnel must notify the sponsor immediatel y if a participant uses any concomitant 
medications not permitted by  [CONTACT_760]. Particip ants who admit to using prohibited 
concomitant medications may be discontinued from the study  at the discretion of the investigator 
or sponsor.
6.5.1. Prohibited Interventions
The decision to administer a prohibited medication/treatment is done with the safet y ofthe 
participant as the primary consideration. When possible, the sponsor must be notified before the 
prohibited medication/treatment is administe red. Co-administration of aminogl ycosides or agents 
that could interfere with neuromuscular transmission (eg, curare -like agents) or muscle relaxants 
must be used with caution as the effects of the toxin, theoret ically, could be potentiated.
No other facial cosmetic procedures or treatments are to be performed throughout the duration of 
the study . Prohibited treatments and procedures include, but are not limited to:
Oral retinoids
New or changes to regimen of topi[INVESTIGATOR_268322]
New or changes to regimen of topi[INVESTIGATOR_268323]
Microdermabrasion to the face
Medium depth to deep facial chemica l peels (ie , TCA and phenol)
Energy -based facial treatments (eg,intense pulsed light, C lear + Brilliant®, monopolar 
radiofrequency , microfocused ultrasound)
Facial lift (mid or full face)
Blepharoplasty
Synthetic implantation (eg, Gore -Tex) to the upper half of the face
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170591] -T-01-01 v2.0
Autologous fat transplantation to the face
Soft- tissue fillers to the face
Permanent make-up to the face
Concurrent treatment with botulinum neuro toxin of an y serot ype for any indication (other 
than the study  intervention )
6.5.2. Permitted Interventions
Any medication (including prescription or over- the-counter medication, vaccines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during t he study must be recorded along with:
Indication
Dates of administration, including start and end dates
Dosage information including dose, frequenc y, and route of administration
Therap y considered necessary  for the participant’s welfare may  be given at the discretion of the 
investigator. If the permissibil ity of a specific medication/intervention is in question, please 
contact [CONTACT_456].
The sponsor must be contact[CONTACT_268330] y.
Any medication taken during the study  between the date of the first dose of study  intervention 
and the date of the end of study visit will be recorded in the eCRF as a c oncomitant medication; 
any medication started afte r the End-of-S tudy Visit will not be considered a concomita nt 
medication and should not be captured in the eCRF.
6.5.3. Rescue Medicine
Not applicable.
6.6. Dose Modification
Any deviation from the planned doses are only at the request of the DMC. After review of safe ty 
and efficacy data, the DMC may  recommend proceeding with the nominal dose for the next 
cohort, request additional data (eg, data from additional participants in the cohort, data from 
visits after Day 14), request to repeat the current dose or a lower dose, request an intermediate
dose be evaluated (between the dose of the current cohort and the nominal dose for the next 
cohort), or request dose escalation be terminated.
6.7. Intervention after the End of the Study
No interventions after the end of stud y are planned.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170592] -T-01-01 v2.0
7. Discontinuation of Study Intervention and Particip ant
Discontinuation/ Withdrawal
A premature discontinuation will occur if a participant who signs the ICF and is dosed ceases 
participation in the study, regardless of circumstances, before the completion of the protocol-
defined stud y procedures.
Notificati on of early participant discontinuation from the study  and the reason for 
discontinuation will be made to the sponsor and will be clearly documented on the appropriate case report form.
Definitions of the standard terms are provided in Appendix 5 .
Reasons for discon tinuation of the study  intervention and/or from the study  may  include the 
following commonl y used terms :
Comm only Used T erms
Adverse event
Com pleted
Lack of efficacy
Lost to follow -up
Other
Physician decision
Pregnancya
Protocol deviation
Site ter minated by [CONTACT_842330] .
7.1. Discontinuation ofStudy Intervention
If a participant does not tolerate stud y injections, the participant will be observed until the
intolerability  has either resolved or satisfactorily  stabilized in the judgement of the investigator,
and the participant may  choose to exit the study  or to remain in the study  for all safet y follow-up
assessments through the End of Study Visit.
See the  SoA for data to be collected at the time of intervention discontinuation and follow- up and 
for an y further evaluations that need to be completed.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170593] -T-01-01 v2.0
7.2. Partici pant Discontinuation/Withdrawal from the Study
A participant may withdraw from the study  at an y time at his/her own request, or may  be 
withdrawn at any time at the discretion of the investigator for safety , behavioral ,
compliance, or administrative reasons.
If the participant withdraws consent for disclosure of future information, the s ponsor may  
retain and continue to use an y data collected before such a withdrawal of consent.
If a participant withdraws fr om the study , he/she may  request destruction of any samples 
taken and not tested, and the investigator must document this in the site study  records.
See the SoA for data to be collected at the time of study discontinuation and follow-up 
and for an y further evaluations that need to be completed.
Women who test positive for urine pregnancy test prior to randomization will NOT 
receive study  intervention and will be discontinued from the study.
7.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
sched uled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.
The following actions must be taken ifa participant fails to return to the clinic fo r a required 
study  visit:
The site must attempt to contact [CONTACT_197651]/or should continue in the 
study .
Before a participant is deemed lost to follow -up, the investigator or designee must make 
every  effort to regain co ntact with the participant (where possible, 3 telephone calls and,
if necessary ,a certified letter to the participant ’s last known mailing address or local
equivalent methods). These contact [CONTACT_842331] ’s 
medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn f rom the study .
Discontinuation of specific sites or of the study  as a whole ishandled as part of Appendix 1.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170594] -T-01-01 v2.0
8. Study Assessm ents and Procedures
Study  procedures and their timing are summarized in the SoA.Protocol waiver s or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the s ponsor immediately  upon 
occur rence or awareness to determine if the participant should continue or discontinue 
study  intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participant s meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to conf irm eligibility  or record reasons for 
screening fai lure, as applicable.
The maximum amount of blood collected from each participant over the duration of the 
study for clinical laboratory and immunogenicity  tests, including any extra assessments 
that may  berequired, will not exceed 250 mL.Repeat or unsche duled samples may be 
taken for safet y reasons or for technical issues with the samples.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170595] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170596] -T-01-01 v2.0
8.1.3. Facial Photography
Standardized digital facial photograp hy will be performed prior to injection of study intervention 
for all participants and at the times shown in the SoA ( Section 1.3). Images will be taken of each 
participant’s face from the front a t rest and at maximum frown. Each site will receive 
documented training and instructions on taking photographs. 
Conditions of photography  will be standardized across all photographs, including camera 
equipment, exposure, backgro und, lighting , and focal length. Ideally , the same photographer will 
take all required photographs. A qualified third- party  vendor will provide instructions for taking
photographs and processing digital photographs. All digital images will be transferred to the 
sponsor at the end of the study . 
Photographs will be taken for research purposes, and may  also be used for education,
commercial, and/or marketing purposes. To participate in this study, the participant must consentto having photographs taken for research but ma y still participate if he/she declines use of the
photographs for other purposes. The sponsor sh all have full ownership rights to any  photographs
derived from the stud y.
8.2. Safety Assessments
Planned timepoints for all safet y assessments are pro vided in the SoA.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170597] 30 minutes following stud y intervention. All p ertinent information regarding adverse events
(ie, date of onset and stop date, duration, outcom e, seriousness, severity, relationship to study  
intervention, treatment required, action taken with study  intervention, etc) will be obtained and 
recorded in the source documents and appropriate eCRF page.
8.2.2. Physical Examinations
A full phy sical examination will be conducted at the Screening Visit and at the End-of-
Study /Early Exit Visit and includes the assessment of general appearance, HEENT, 
heart/ cardiovascular function , lungs, abdomen, extremities, back, musculoskeletal function, 
lymphatic function , neurologic function , and skin .Abbreviated physical examinations will be 
conducted throughout the study as described in the SoA and limited to an exam ination of general 
appearance, heart, lungs, and abdomen.
Before stud y intervention, if the phy sical examination finding is clinically significant, the finding 
must be captured in the medical history  eCRF. After study  intervention, if the pre -existing 
finding becomes worse and is clinically significant or the new physical examination finding is 
clinically signific ant, itmust be capture d as an adverse event in the adverse event eCRF.
8.2.3. Neurologic Assessment
The neurologic assessment comprises [ADDRESS_1170598] be performed prior to randomization on 
Day 1, and is to be performed after adverse event assessment at all subsequent timepoints. See 
Appendix 8 for instructions for both elements.
Participants with any  abnormal findings at Screening or Day 1 (prior to randomization ), which 
meet exclusion criteria or ma y impact a participant’s safety or the interpretation of ef ficacy ,will 
be excluded from the study .For partic ipants who meet the inclusion/exclusion criteria, images of 
the face at natural smile and at rest will be captured at Day 1(prior to randomizatio n)in order to 
document baseline gross facial s ymmetry . The se images will be referenced for the Focused 
Neurol ogic E xamination.
8.2.4. Vital Signs
Vital signs will be assessed as follows:
Pulse rate (beats per minute): Participant s are to be seated for at least 2 minutes, and 
pulse rate will be counted over 60 seconds and recorded in the source document and 
eCRF as beats per minute.
Blood pressure (mm Hg): Participant s are to be seated for at least 2 minutes, and 
systolic/diastolic b lood pressure will be measured.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170599] -T-01-01 v2.0
Respi[INVESTIGATOR_1487] (breaths per minute): Participant s are to be seated for at least 2 minutes, 
and breaths wil l be counted for 30 seconds and multiplied by 2.
When applicable, vital sign data willbe collected prior to blood draws .
Body temperature will be taken.
Before study intervention, if the vital sign findi ng is clinically  significant, itmust be capture d in 
the medical history  eCRF. After study intervention, if the pre -existing finding becomes worse 
and is clinically  significant or the new vital sig n finding is clinicall y significant, it must be 
capture das an adverse event in the adverse event eCRF.
8.2.5. Elect rocardiogram s
All participants will undergo conventional 12-lead ECG using standardized equipment 
and electrode placement at the visits outlined in the SoA. Participants are to be in a 
semirecumbent position for at least 10 minutes prior to starting the tr acing. During 
screening, a 12- lead ECG trace will be taken to assess entry  eligibility .
A qualified third- party vendor will read the ECGs and repo rt the findings as normal, 
abnormal, or unable to evaluate.
For screening ECGs, prespecified significant abnormal findings w ill be flagged as 
exclusion alerts, and a third- party vendor will generate an exclusion alert for the site and 
the sponsor. Exclusio n alert s are considered exclusionary  for study  eligibility (see 
Exclusion Criterion 1.05 in Sec tion 5.2 which excludes an y participant with a ‘clinicall y 
significant ECG abnormality  at the Screening Visit ’). For all subsequent ECGs, a 
qualified third- partyvendor will al so report the appearance of an y new, prespecified 
significant abnormal findings and generate a protocol alert for the site and the sponsor.
The cardiologists will be blinded to participant study intervention assi gnments. If the 
ECG finding is abnormal, they will specify  the abnormality  or give a diagnosis, whenever 
it ispossible. Electrocardiogram reports will be provided to the investigator and the 
sponsor via a secure portal within 24 hours of screening and within 72 hours for all other visits.
Before st udy intervention, if the ECG finding is clinically  significant, itmust be capture d
in the medical history  eCRF. After stud y intervention, if the pre -existing finding becomes 
worse and is clinicall y significant o r the new ECG finding is clinicall y significant, itmust 
be capture d as an adverse event in the adverse event eCRF. Hard copi[INVESTIGATOR_842321]’s site.
The ECG will be assessed for the following: heart rate, QRS duration, QT interval, QTcB interval, QTcF interval, ST segment, RR interval, PR interval, and qualitative results.
8.2.6. Clinical Safety Laboratory Assessments
SeeAppendix 2for the list of clinical laboratory  tests to be performed and the SoA for 
the timing and frequency.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170600] -T-01-01 v2.0
At screening, the investigator will assess the clinical significance of an y values outside 
the reference ranges provided by [CONTACT_25699] , and participants with abnormalities 
judged to be clinically s ignificant will be excluded from the study.
The investigator must review the laboratory report, document this review, and record an y 
clinically  relevant changes occurring during the study in the adverse event section of the 
eCRF. The laboratory  reports must be filed with the source documents. Clinic ally 
significant abnormal laboratory findings are those which a re not associated with the 
underlying disease, unless judged by  [CONTACT_842332] ’s condition.
Alllaboratory  tests with values considered clinically  significant during participation in 
the study , including t he End-of-Study /Earl y Exit Visit, should be repeated until the values 
return to normal or baseline or are no longer considered clinically significant by  [CONTACT_842333] .
oIf such values do not return to normal/baseline within a period of time judged
reasonable by [CONTACT_093], the etiology should be identified and the sponsor 
notified.
oAll protocol- required laboratory  assessments, as defined in Appendix 2, must be 
conduct ed in accordance with the laboratory manual and the SoA.
oIf laboratory  values from nonprotocol specified laboratory assessments performed 
at the institution’s local laboratory require a change in participant management or 
are considered clinically  significant b y the investigator (eg, SAE or adverse eve nt
or dose modification), then the results must be recorded in the eCRF.
8.2.7. Urine Pregnancy Test
Urine dipstick kits will be used to conduct pregnanc y tests at the timepoints specified in the SoA, 
or more frequently at the investigator’s discretion.
8.2.8. Suicidal Risk Monitoring
Suicidal risk monitoring is not applicable for this study .
8.3. Adverse Events and Serious Adverse Events
The definitions of an adverse event or SAE can be found in Appendix 3 .
Adverse events will be reported by  [CONTACT_2299].
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definitio n of an adverse event or SAE and remain responsible for 
following up adverse events that are serious, considered related to the study intervention or study  
procedures, or that caused the participant to discontinue the study intervention (see Section 7).
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170601] -T-01-01 v2.0
8.3.1. Time Period and Frequency for Collecting A dverse Event and S erious A dverse 
Event Information
All SAEs and adverse events from the signing of the I CFwill be collected at the timepoints 
specified in the SoA (Section 1.3), and as observed or reported spontaneously  by [CONTACT_542438].
Medical occurrences that begin before the start of study intervention, but after obtaining 
informed consent will be recorded in the adverse event section o f the e CRF and will be 
consi dered pretreatment adverse events.
All SAEs will be recorded and reported to the sponsor or designee within 24 hours, as indicated in Appendix 3. The investigator will submit any updated SAE data to the sponsor within 
24 hours of it being available.
Investigators are not obligated to activel y seek adverse ev entor SAE information after 
conclusion of the study participation . However, if the investigator learns of any SAE, including a 
death, at an y time after a participant has bee n discharged from the study , and he/she considers 
the event to be reasonably relat ed to the study intervention or study participation, the investigator 
must promptly  notify  the sponsor.
The method of recording, evaluating, and a ssessing causality  of adverse events and SAEs and the 
procedures for completing and transmitting SAE reports are provide d in Appendix 3.
8.3.2. Method of Detecting A dvers e Event s and S erious A dverse Events
Care will be taken not to introduce bias when detecting adverse events and/or SAEs. O pen-ended 
and nonleading verbal questioning of the participant is the preferred method to inquire about 
adverse event occurrences.
8.3.3. Follow -up of Adverse Events and Serious Adverse Events
After the initial adverse event/SAE report , the investi gator is requir ed to proactivel y follow each 
participant at subsequent visits/contacts. All adver se event s/SAEs will be followed until 
resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up 
(as def ined in Secti on 7.3).
The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_325740]/or causalit y of the adverse event or SAE as fully  as possi ble. This may  
include additional laboratory  tests or invest igations, histopathological examinations, or 
consultation with other health care professionals.
If a participant dies during participation in the study  or dur ing a recognized follow-up period, the 
investigator will provide the sponsor with a cop y of an y postmortem findings including 
histopathology. 
New or updated information will be recorded in the originally  completed eCRF.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170602] -T-01-01 v2.0
The investigator will s ubmit any  updated SAE data to the sponsor within 24 hours of receipt of 
the information.
8.3.4. Regulatory Reporting Requirements for Serious Adverse Events
Prompt notification by  [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of 
a study  intervention under clinical investigation are met. 
The sponsor has a legal responsibility  to notify  both the local regulatory authority  and 
other regulatory  agencies ab out the safe ty of a study  intervention under clinical 
investigation. The sponsor will comply  with country -specific regulatory requirements 
relating to safet y reporting to the regulatory  authority , IRBs/IECs, and i nvestigators.
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAEs) from the sponsor will 
review and then file it along with the IBand will notify  the IRB/IEC, if appropriate 
according to local requiremen ts.
Investigator safety  reports must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy  and forwarded to investigators as necessary.
8.3.5. Pregnancy
Details of all pregnancies, including pregnancy  outcome, in female participants and 
consent ed female partners of male participants will be collected; pregnancies include 
those with onset af ter study  intervention, and until 10 weeks after study  intervention for 
female participants and until 6 weeks after stud y intervention for female partners of male 
participants.
At each visit, site personnel must discuss with WOCBP and males with partners who are 
WOCBP compliance with contraceptive use.
Urine pregnancy  testing will be conducted for WOCBP at the Screening Visit, prior to 
randomization at Day 1,at thestudy  exit visit, and at the discretion of the investigator. 
See Appendix 7 for detailed information on definition of WOCBP, use of contraceptives,
and pregnancy .
Women who test positive for urine pregnancy  test prior to randomization will NOT 
receive treatment and will be discontinued from the study.
If a pregnancy is confirmed after the participant has received s tudy intervention, the 
participant may choose to exit the study  after appropriate safet y follow-up or remain i n 
the study  for all safet y and efficacy  follow- up assessments.
Any termination of pregnancy will be reported, regardless of fetal status (presenc e or 
absence of anomalies) or indication for the procedure.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170603] -T-01-01 v2.0
If a pregnancy is reported, the invest igator should inform the sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 7.
Abnormal pregnancy  outcomes (eg, spontaneous or elective abortion, fetal death, 
stillbirth, congenital a nomalies, ectopic pregnancy ) or genetic abnormalities (whether 
leading to an elective abortion or not) are considered SAEs.
8.3.6. Adverse Events of Special Interest
There are no AESI s for this study because they  are not clinically  indicated. 
8.3.7. Medication Errors
Medication error refers to any  unintende d error in the dosing and/or administration of the study 
intervention as per instructions in the protocol. Medication errors generall y fall into 4 categories 
as follows:
Wrong study  intervention
Wrong dos e (including dosing regimen, strength, form, concent ration, amount)
Wrong route of administration
Wrong partic ipant (ie, not administered to the intended participant)
Medication errors include occurrences of overdose and underdose of the study intervention .
Overdose: Unintentional administration of a quanti ty of the stud y intervention given per 
administration that is above the maximum recommended dose according to the protocol for the 
study  intervention. See  Section 8.4for information of treatment of overdose.
Underdose: Unintentional administration of a quantity  of the study  intervent iongiven per 
administration that is under the minimum recommended dose according to the protocol. 
8.4. Treatment of Overdose
Overdose of AGN -151586 is a relative term and depends upon dose, site of injection, and 
underly ing tissue properties. Signs and s ymptoms of overdose are likel y not to be apparent 
immediately postinjection. Excessive doses may  produce local, or distant, generalized and
profoun d neuromuscular paral ysis.
Because AGN -151586 is administered as injections by  [CONTACT_13922], for this study, the cha nce of 
overdose is extremely low. Should accidental injection occur or overdose be suspected, the 
participant should be medically moni tored for up to several weeks for progressive signs or 
symptoms of sy stemic muscular weakness that could be local or distant from the site of injection, 
which may  include ptosis, diplopia, dy sphagia, d ysarthria, generalized weakness, or respi[INVESTIGATOR_7518] . Eyelidptosis, diplopia, or vision blurred are known local effects of BoNT/A during 
treatment of glabellar lines, which may also occur with BoNT/E. These participants should be 
considered for further medical evaluation and appropriate medical therap y immediately
instituted, which may include hospi[INVESTIGATOR_059].
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170604]. Supportive care could involve the need for a tracheostomy and/or prolonged mechanical 
ventilation, in addition to other general supportive care.
In the event of an overdose , the investigator should:
1. Contact [CONTACT_842334].
2.Closely  monitor the participant for an y AE/SAE.
3. Document the quantity of the excess dose in the eCRF.
8.5. Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study .
8.6. Pharmacodynamics
Pharmaco dynamic parameters are not evaluated in this study .
8.7. Genetics
Genetics are not evaluated in this study .
8.8. Biomark ersand Other Assessments
Immunogenicity Assessments
Validated assay s will be used to assess the presence of antidrug antibodies to A GN-151586, 
using blood samples collected during the course of the study .  
Blood samples for immunogenicity  testing will be collected from each participant at Screening, 
and at the Day  7, Day 28, and End-of-Study visits. Collected samples (approximately  [ADDRESS_1170605] e) will be processed to y ield serum for analy sis.
Detection of binding antibodies against AGN- 151586 in participants’ serum will be carried out
using the validated ELISA in a 3-tier format (screening, confirmation, and titering). Only 
samples that are conf irmed positive in the confirmatory  assay will be stored and analyzed for
presence of neutralizing antibodies t o AGN- 151586 when a validated assay becomes available.
These samples may also be used for additional characterization of antibody  response to othe r 
neurotoxin subty pe(s). The findings from this exploratory  anal ysiswill be documented in the 
clinical st udy report or in a separate report. T he ICF will contain a separate appendix that 
addresses the use of immunogenicity  samples for this optional ex ploratory  research. The 
investigator or his/her representative will explain to each participant that t heir par ticipation is 
voluntary . With regards to using their blood samples for this exploratory  characterization of 
antibody  response to other neurot oxin subty pe(s) ,participant s may  give consent, refuse to give 
consent, or may  give consent and la ter withdraw their consent at any  time and for an y reason 
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170606] -T-01-01 v2.0
during the storage period. A separate signature [CONTACT_22862] a participant's 
agreement or refusal to allow specimens to be used for this exploratory  research. 
8.9. Medical R esource Utili zation and Health Eco nomic s
Medical resource utilization and health economics parameters are not evaluated in this study .
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170607] -T-01-01 v2.0
9. Statistical Considerations
9.1. Statistical Hy potheses
The following hypotheses will beused tocompare each dose group ofAGN -151586 with
placebo:
Null hypothe sis:AGN-151586 andplacebo areequally effective inthe probability of 
reducing GLseverity atmaximum frown asmeasured bya ≥ 2-grade improvement from
baseline based onthe investigator -rated FWS atany post treatment timepoint through Day 7.
Alternative h ypothesis: AGN -151586 and placebo are not equally effective inthe 
probability  of reducing GLseverity atmaximum frown as measured bya ≥2-grade
improvement from baseline based ontheinvestigator -rated FWS at any  posttreatment 
timepoint through Day  7.
9.2. Sample Size Determination
For each cohort, there will be approximately 40 participants ( AGN- 151586: n = 30;placebo: 
n=1 0) with a 3:1 randomization allocation; up to 5 dose cohorts are planned. For a cohort of 30 
participants treated with AGN-151586, there is an approximately  60% chance of detecting an
adverse event which occurs at a 3 % incidence (eg, eyelid ptosis) .
Approxim ately200participants will be randomized to have approximately 180 participants 
complete the study  based on an anticipated dropout rate of 10%. Approximately 150participants
are expected to have a single dose exposure toAGN -151586 with an approximately 78% chance to
detect anyadverse event ata 1% incidence, and a 9 5% chance to detect an y adverse event at a 
2% incidence.
The primary efficacy analy sis will be conducted on the mI TT population, which consists of 
randomized participants who have been dosed and have a post treatment measurement of 
investigator- rated FWS at maximum frown. A sample size of [ADDRESS_1170608] 
approxi mately  87% power to detect a difference between an AGN-151586 dose group and the 
placebo group, assuming a 10% dro pout rate and responder rates of 70% for the AGN-151586 
study  intervention group and 10% for the placebo group.
The calculation is based on a 2-sided Chi- squared test (Fisher’s exact test) with a 0.[ADDRESS_1170609] treatment investigator- rated 
FWS measurement at maximum frown. The safety anal ysiswill be performed using the safet y 
population that includes all participants who received study  intervention .All analy ses will be 
performed on an as-treated basis.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170610] -T-01-01 v2.0
9.4. Statistical Analyses
The SAP will be developed and finalized before database lock and unblin ding, and will describe 
the participant populati onsto be included in the analy ses, along with procedures for accounting 
for missing, unused, and spurious data. This section is a summary  of the planned statistical 
analyses of the primary  and exploratory endpoints .
9.4.1. Efficacy Analyses
[IP_ADDRESS]. Primary Efficacy Endpoints
The efficacy endpoint is t he achievement of a ≥ 2-grade improvement from baseline on the FWS 
according to investigator assessments of GL severity  at maximum frown at any  postintervention 
timepoint thr ough Day 7.
[IP_ADDRESS]. Primary Efficacy Analyses
The purpose of the primary  anal yses isto test for the primary  endp oint, that is, the achievement 
of a ≥2-grade improvement in FWS according to investigator assessments of GL severity  at 
maximum frown from Day 1 through Day 7 for each cohort. Safet y will be assessed b y the 
DMC.
The purpose of the primary  anal yses will be to test for the primary  endpoint (ie, at least a
2-grade improvement response from investigator) during an y timepoint after study
intervention admini stration through Day  7for each AGN -[ADDRESS_1170611] a 2- grade improvement at an y postintervention 
assessment through Day  7, they  will meet the responder definition for each assessment 
timepoint this applies.
The proportion of responders for the primary endpoint for each AGN -151586 study  
intervention group versus placebo will be anal yzed using CMH tests stratifi ed by [CONTACT_842335] y at maximum frown, using observed data without imputation or adjustment 
for multiplicity . In addition, 2-sided 95% CIs for the treatment differences in response 
rates will be provided. Between group comparisons will only  be perfor med for each 
AGN-[ADDRESS_1170612].
Observed data without imputation will be used with stratification based on baseline GL 
severit yfor the primary  analy sis described above. In addition, sensitivity  analy ses of the 
primary  efficacy  variable will be performed to establish consistency  and robustness and
further characterize the extent of participants’ responses (eg, missing as nonresponder). In addition, placebo groups across cohorts can be pooled to compare with each AGN-151586 group as a supportive analy sis.  Details will be provided in the SAP.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170613] -T-01-01 v2.0
Baseline and posttreatment values will be summarized using descriptive statistics for the AGN-
151586 dose groups and placebo group for each cohort a t each assessment timepoint. D etails will 
be provided in the SAP.
9.4.2. Safety Analyses
The safet y analysis will be performed using th e safety population and will be defined in the SAP. 
The safet y parameters will include:
Incidence of a dverse events, including adverse event severit y and causalit yas assessed b y 
the investigator
Change from baseline and values over time in clinical labora torytests, physical 
examinations, vital signs, and ECGs
[IP_ADDRESS]. Adverse Events
An adverse event will be considered a TE AEif:
The adverse event began on or after the date and time of the study  intervention ; or
The adverse event was present before the date a nd tim e ofthe study  intervention ,but 
increased in severit y or became serious on or after the date and time of thestudy  
intervention.
An adverse event that occurs after the End- of-Study Visit (Day  42) will not be counted as a 
TEAE.
An adverse event will be considered a TESAE if it is a TEAE that additionally  meets an y SAE 
criteria.The number and percentage of participants reporting TEAEs in each study  intervention group
will be tabulated b y system organ class and preferred term andby [CONTACT_9313], preferred
term, and severity.The number and percentage of participants reporting treatment- related TEAEs in each stud y 
intervention group will be tabulated b y system organ class and preferred term.
If more than [ADDRESS_1170614] will be included in 
the SAP.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170615] -T-01-01 v2.0
Summary  tables will be provided for participants with TESAEs and participants with TEAEs
leading to discontinuation if 5 or more participants reported such events. Listing s of all adverse 
events , SAEs, and adverse events leading to discontinuation by [CONTACT_217664].
The definitions of an adverse event and SAE can be found in Appendix 3.
[IP_ADDRESS]. Clinical Laboratory Assessments
Descriptive statistics for clinical laboratory  values (in SI  units) at baseline (screening) and 
changes from baseline at each assessment will be presented b y study  intervention for each 
clinical laboratory  assessment.
The criteria for PCS laboratory  values will be detailed in the SAP. The number and percentage of 
participants who have PCS postbaseline clinical laboratory values will be tabulat ed by [CONTACT_842336]. The percentages will be calculated relative to the number of 
participants who have available non-PCS baseline values and at least [ADDRESS_1170616] 1 PCS postbaseline value. A 
supportive listing of participants with PCS postbaseline values will be provided for the safet y 
population. 
[IP_ADDRESS]. Vital Signs
Descriptive statistics for vital signs (s ystolic and diastolic blood pressure, pulse rat e, respi[INVESTIGATOR_11943], body  temperature) at baseline prior to receiving study  intervention ( or screening value just 
prior to baseline if baseline values are not available ) and changes from baseline at each 
assessment will be presented by [CONTACT_842337] .
The criteria for PCS vital signs will be detailed in the SAP. The number and percentage of 
participants who have PCS postbaseline vital signs will be tabulated by [CONTACT_842338]. The percentages will be calculated relative to the num ber of participants who 
have available non-PCS baseline values and at least [ADDRESS_1170617] 1 PCS postbaseline value. A supportive 
listing of participants with PCS postbaseline values will be provided for the s afety population.
[IP_ADDRESS]. Electrocardiograms
Electrocardiogram evaluations by  [CONTACT_842339] 3 
categories: normal, abnormal, or not evaluable. These data will be summarized by  [CONTACT_842340]. Data 
listings which include ECG basic parameters and any ECG abnormalities will be produced.
9.4.3. Other Analyses
[IP_ADDRESS]. Immunogenicity Analyses
Immunogenicity results, manifes ted as the presence of binding a ntibodies, and neutralizing 
antibodies if a validated assay becomes available, to AGN-151586, will be summarized in a table
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170618] -T-01-01 v2.0
and reported for each sampling timepoint. Additional immunogenicity exploratory  anal yses may  
be performe d; results will be summarized in the clinical study  report or in a separate report.
9.5. Interim Analyses
No interim anal ysis is planned.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170619] -T-01-01 v2.0
10. Supporting Documentation and Operational Considerations
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170620] -T-01-01 v2.0
10.1. Appe ndix 1: Regulatory, Ethical, and Study Oversight 
Considera tions
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following :
oConsensus ethic alprinciples derived from international guidelines including the 
Declaration of Helsinki and Council for Intern ation al Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines
oApplicable ICH /ISOGood Clinical P ractice (GCP) guidelines
oApplicable laws and regulations
The protocol, protocol amendments, I CF, investigator’s brochure, and other relevan t 
documents (eg, advertisements) must be submitted to an I RB/IEC by  [CONTACT_31846]/IEC before the study  is initiated. 
Any amendments t o the protocol will require IRB/I EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants. 
The investigator will be responsible for the following:
oProviding written summaries of the status of the study to the IRB/I EC annually  or more 
frequently in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/IEC
oNotify ing the IRB/IEC of SAE s or other significant safet y findings as required by 
[CONTACT_1744]/IEC procedures
oProviding oversight of the overall conduct of the study  at the site and adherence to 
requirements of applicable local regulations, for example 21 CFR, I CH guidelines, the 
IRB/IEC, and European regulation 536/2014 for clinical studies (if applicable)
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the participant or his/her legally authorized representative and answer all questions regarding the 
study . 
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170621] -T-01-01 v2.0
Participants must be informed that their p articipation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 C FR 50 , 
local regulations, ICH guidelines, HIPAA requirements, where applicable, and the IRB/IEC 
or study  center. 
The medica l record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and th e dat e the written consent was obtained. 
The authorized person obtaining the informed consent must also sign the ICF.
Participants must be reconsented to the most current version of the ICF(s) during their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s legall y 
authorized representative. 
Participants who are rescreened are not required to sign a new ICF if rescreening occurs 
within [ADDRESS_1170622] signing the ICF.
10.1.4. Data Protection
Participants will be assigned a unique identifier. Any participant records or datasets that are 
transferred to the sponsor will contain the identifier only ; participant names or any  
information which would make the participant identifiable will not be transferred. 
The par ticipant must be informed that his/her personal study -related data will be used by [CONTACT_20004]. The level of disclosure must also be explained to the participant. 
The participant must be informed that hi s/her m edical records may be examined by [CONTACT_160439], by  
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
10.1.5. Posting Clinical Study Data
Study  data and informat ion m ay be published in nonpromotional, peer-reviewed publications 
either by [CONTACT_82298]. 
Clinical study reports, safety  updates, and annual reports will be provided to regulatory 
authorities as required.
Company -sponsored study  informatio n and tabular study  results will be posted on the US 
National Institutes of Health’s website www.ClinicalTrials.gov and other publicly accessible sites.
10.1.6. Data Quality Assurance
All participant data relating to the stud y wil l be recorded on printed or e CRF s unles s 
transmitted to the sponsor or designee electronically  (eg,laboratory  data). The investigator is 
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170623] by  [CONTACT_842341].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents. 
The sponsor or designee is responsible for the data management of this study including 
quality  checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the e CRF by [CONTACT_95499] , complete, and verifiable from source 
documents; that the safety  and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently approved protocol and any  other study  
agreements, ICH GCP, and all applicable regulatory requirements. 
Records and documents, including signed ICFs, pertaining to the conduct of this study  must 
be retained b y the investigator as stated in the clinical trial agreement. No records may be 
destroy ed during the retention per iod without the written approval of the sponsor . No records 
may be transferred to another location or party without written notification to the sponsor.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate theintegrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be ex plained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . 
Definition of what constitutes source data can be found in Section 4.0 of ICH E6, Good Clinical Practice: Consolidated Guidance and mu st follow AL COA, ie, records must be 
attributable, legible, contemporaneous, original, and accurate.
All study  photographs will be uploaded to a secure server via the internet. Secure digital 
cards will remain at the site and serve as the source documentat ionfor subject photographs. 
10.1.8. Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for an y reason at the sole discretion of the sponsor. Study sites will be closed upon study
completion. A study  site is considered closed when all required documents and study supplies 
have been collected and a study-site closure visit has been performed.
The investigator may initiate study -site closure at any  time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170624] -T-01-01 v2.0
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply with the protocol, the requirements of th e IRB/IEC or 
local health authorities, the sponsor’s procedures, or GCP guidelines
Inadequate recruitment of participants by  [CONTACT_093]
Discontinuation of further study  intervention development
10.1.9. Publication Policy
Allergan as the sponsor has proprieta ry interest in this study . Authorship and manuscript
composition will reflect joint cooperation between multiple investigators and sites and
Allergan personnel. Authorship will be established prior to the writing of the manuscript. As 
this study  involves m ultiple centers, no individual publications will be allowed prior to 
completion of the final report of the multicenter study except as agreed with Allergan.
The sponsor will comply with the requirements for publication of study  results. I n
accordance with standard editorial and ethical practice, the sponsor will generall y support
publication of multicenter studies only  in their entirety  and not as individual site data.
Authorship will be determined by  [CONTACT_11403] I nternational Committe e
of Medical Journal Editors authorship requirements.
10.1.10. Compliance with Protocol
The investigator is responsible for compliance with the protocol at the investigational site. A 
representative of the sponsor will make fre quent contact [CONTACT_842342] d his /her 
research staff and will conduct regular monitoring visits at the site to review participant and 
study  intervention accountability  records for compliance with the protocol. Protocol deviations 
will be discussed with the investigator upon identification. The use of the data collected for the 
participant will be discussed to determine if the data are to be included in the anal ysis. The 
investigator will enter data that may be excluded from anal ysis as defined by [CONTACT_78587]. Significant protocol deviations will be reported to the I RB/IEC 
according to the IRB/IEC’s reporting requirements.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170625] -T-01-01 v2.0
10.2. Appendix 2: Clinical Laboratory Tests
The tests detailed in Table 10-1 will be performed by  [CONTACT_2237] .
Protocol- specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
Additional tests may  be performed at an y time during the study as determined nece ssary  by 
[CONTACT_842343].
Table 10-[ADDRESS_1170626] (SGOT) Hem atocrit (PCV)
ALT (SGPT) RBC count
GGT MCV
LDH RDW
Alkaline phosphatase MCH
Total protein MCHC
Albumin WBC count and differentialc
Calcium -Neutrophil count
Creatinine -Lymphocyte count
BUN -Monocyte count
Sodium -Basophil count
Potassium -Eosinophil coun t
Bicarbonate Platelet cou nt
Chloride
Inorganic phosphate Urinalysis
Uric acid Color
Glucose Appearance
Magnesium pHSpecific gravity
Other
Glucose
Urine pregnancybProtein
Ketone
BloodUrine microscopy
d
ALT = alanine aminotransferase (= serum glutamic pyruvic tra nsaminase [SGPT]); AST = aspartate aminotransferase (= serum 
glutamic oxaloacetic transaminase [SGOT]); BUN = blood urea nitrogen; GGT = glutamyl -transferase; LDH =lactate 
dehydrogenase; MCH = mean cell hemoglobin; MCHC =mean cell hemoglobin concentrat ion; MCV =mean (re d) cell volume; 
PCV=packed cell volume; RBC = red blood cell; RDW = red (cell) distribution width; WBC = white blood cell (leukocyte)
aLaboratory samples for hematology, chemistry, and urinalysis testing will be collected under random conditions; partic ipants do 
not need to be fasting.
bUrine pregnancy tests are performed only in females of childbearing potential and must be conducted at the investigational site.
cDifferential count to be provided as absolute counts for neutrophils, lymphocytes, monocytes, basophils, and eosinophils (rather 
than as percentages of WBC)
dCrystals, casts, RBC, WBC, bacteria
Investigators must document their review of each laboratory safet y report.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170627] -T-01-01 v2.0
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or intervention that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084] . If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether hospi[INVESTIGATOR_51956] , the AE 
should be considered serious.
Hospi[INVESTIGATOR_287408] a pre- existin g condition that did not wo rsen 
from baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions bu t do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may  
not be immediately  lifethreatening or result in death or hospi[INVESTIGATOR_473371]. These events s hould usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive intervention in an emergency  room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug depe ndency  or drug abuse.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170628] -T-01-01 v2.0
10.4. Appendix 4: Abbreviations
AESI adverse event of special interest
AUC area under the curve
AUC 12-[ADDRESS_1170629] -surgery
BoNT/A Botulinum Neurotoxi n Seroty pe A
BoNT/E Botulinum Neurotoxin Seroty pe E
CIOMS Council for International Organizations of Medical Sciences
CMH Cochran -Mantel -Haenszel
COA clinical outcome assessment
CONSORT Consolidated Standards of Reporting Trials
DAS digital abduction score
DMC data monitoring committee
ECG electrocardiogram
eCRF electronic c ase report form
ELISA enzyme-linked immunosorbent assay
ire
FWS Facial Wrinkle Scale With Photonumeric Guide
FWS-IA Facial Wrinkle Scale – Investigator Assessment
GCP Good Clinical Practice
GL glabellar lines
HEENT head, ey es, ear, nose, and throat
IB investigator’s brochure
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use
ICF informed consent form
IEC independent ethics committee
IM intramuscular
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170630] -T-01-01 v2.0
IR-2 Investigator assessment of a 2-grade improvement (reduction) 
from baseline in GL severity
IRB institutional review board
ISO International Organization for Standardization
IWRS interactive web response sy stem
LCL lateral canthal lines
mITT modified intent- to-treat
MSP medical safety  physician
NOAEL no-observed -adverse-effect level
PCS potentially  clinicall y significant
PDSOT possible distant spread of toxin
SAE serious adverse event
SAP statistical analy sis plan
SI Le Système International d’Unités (International System of Units)
SoA schedule of assessments
S[LOCATION_003]R serious adverse reactions
TCA trichloroacetic acid
TEAE treatment -emergent adverse event
TESAE treatment -emergent serious adverse event
USB universal serial bus
VAS Visual Analog Scale
WOCBP woma n of childbearing potential
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170631] -T-01-01 v2.0
10.5. Append ix 5: Standard Discontinuation Criteria
CDISC Submission Value CDISC Definition
Adverse event Any untoward medical occurrence in a patient or 
clinical investigation participant administered a 
pharmaceutical product and which does not necessarily have a ca usal relationship with this
treatment. An adverse event (AE) can therefore be any unintended sign (including an abnormal 
laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the me dicinal (investigational) product. For further 
information, see the ICH Guideline for Clinical Safety Data Management: Definitions and 
Standards for Expedited Reporting (modified from 
ICH E2A )Synonyms: side effect, adverse 
experience. See also serious adverse event, serious 
adverse experience. (CDISC glossary)
Com pleted To possess every necessary or normal part or 
component or step; having come or been brought to 
a conclusion (NCI)
Death The absence of life or state of being dead (NCI)
Disease relapse The return of a disease after a period of remission
Failure to meet randomization criteria An indication that the participant has been unable 
to fulfill/satisfy the criteria required for assignment into a randomized group
Lack of efficacy The lack of expected or desi red effect related to a 
therapy (NCI)
Lost to follow -up The loss or lack of continuation of a participant to 
follow -up
Non-compliance with study drug An indication that a participant has not agreed with 
or follow ed the instruct ions related to the study 
medication (NCI)
Other Different than the one(s) previously specified or mentioned (NCI)
Physician decision A position, opi[INVESTIGATOR_842322] a physician with reference to participant (NCI)
Pregnancy Pregnancy is the state or condition of having a 
developi[INVESTIGATOR_78527] (uterus), 
after union of an ovum and spermatozoon, during 
the period from conception to bi rth. (NCI)
Progressive disease A disease process that is increasing in exten t or 
severity (NCI)
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170632] to the 
guidelines set out by [CONTACT_760] (NCI)
Recovery A healing process and/or an outcome implying 
relative health. The term is typi[INVESTIGATOR_842323]. (NCI)
Screen failure The potential participant who does not meet one or 
more criteria required for participation in a trial
Site terminated by [CONTACT_78588] a clinical study was stopped at a 
particular site by [CONTACT_23662] ( NCI)
Study terminated by [CONTACT_78588] a clinical study was stopped by 
[CONTACT_23662] (NCI)
Technical problems A problem with some t echnical aspect of a clinical 
study, usually related to an instrument (NCI)
Withdraw al by [CONTACT_7078]/guardian An in dication that a study participant has been 
removed from the study by [CONTACT_842344] a study participant has removed 
itself from the study (NCI)
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170633] -T-01-01 v2.0
10.6. Appendix 6: Study Tabular Summary
Param eter Group Param eter Value
Trial information Trial Title A Phase 2b Double -Blind, Placebo -
Controlled, Dose -Ranging Study to 
Evaluate the Safety and Efficacy of 
AGN- 151586 in Participants With 
Moderate to Severe Glabellar Lines
Clinical S tudy Sponsor Allergan Sales LLC
Trial Phase Classification Phase 2b
Trial Indication Glabellar lines
Trial Indication Type Treatment
Trial Type Efficacy
Safety
Trial Length 72days (from the Screening to Day 42
visits)
Planned Country of Investigational Sites United Sta tes
Planned Number of Participant s 200
FDA -Regulated Device Study No
FDA -Regulated Drug Study Yes
Pediatric Study No
Participant
informationDiagnosis Group Presence of GL of moderate to severe rating at maximum frown
Healthy Participant Indicat or No
Planned Minimum Age of Participant s 18
Planned Maximum Age of Participant s 65
Sex of Participants Male or Female
Stable Disease Minimum Duration Not applicable
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170634] -T-01-01 v2.0
10.7. Appendix 7: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanentl y sterile (see below).
Women in the following categories are not considered WOCBP:1.Premenarchal
2. Premenopausal female with 1 of the following:
Documented h ysterectomy
Docu mented bilateral salpi[INVESTIGATOR_61502]
Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of the participant ’s 
medical records, medical examination, or medical history  interview.
3. Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle -stimulating hormone (FSH) level in the postmenopausal 
range may  be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therap y (HR T). However , in the absence of 
12 months of amenorrhea, a single FSH measurement is insufficient. 
Females on HR T and whose menopausal status is in doubt will be required to use one of
the nonestrogen hormonal highly  effective c ontraception methods if they wish to continue 
their HR T during the study. Otherwise, they  must discontinue HR T to allow confirmation 
of postmenopausal status before study  enrollment .
Contracept ionGuidance:
Male ParticipantsNonvasectomized m ale participan ts with female partners of childbearing potential are eligible to 
participate if they agree to ONE of the following during the study and for at least 6 weeks after 
administration of study intervention : 
Are abstinent from penile-vaginal intercourse as their us ual and preferred lifest yle 
(abstinent on a long-term and persistent basis) and agree to remain abstinent
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170635] -T-01-01 v2.0
Agree to use a male condom with spermicide plus partner use of a contraceptive method 
with a failure rate of < 1% per y ear as described in Table10-[ADDRESS_1170636] 6 weeks after administration of study  
intervention.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170637] -T-01-01 v2.0
Pregnancy Testing:
Pregnancy testing will be per formed according to instructions provide d in the pregnancy  
test kit .
WOCBP  should only be included after a confirmed menstrual period and a negative urine
pregnancy  test at Day  1.
Additional pregnancy  testing is not required during the study other than at the End -of-
Study /Earl y Exit V isit.
Pregn ancy  testing will be performed whenever a menstrual cy cle is missed or when 
pregnancy  is otherwise suspected at the discretion of the investigator.
Collection of Pregnancy Information:
Male Participants with Partners Who Become Pregnant 
The investigator w ill attempt to collect pregnancy information on any  male participant’ s 
female partner who becomes pregnant while the male participant is in this study . This 
applies only  to male participants who receive study  interve ntion.
After obtaining the necessary sig ned informed consent from the pregnant female partner 
directly , the investigator will record pregnancy information on the appropriate form and 
submit it to the sponsor within 24 hours of learning of the partner ’s pregnancy . The female 
partner will also be followed to determine the outcome of the pregnancy. Information on 
the status of the mother and child will be forwarded to the sponsor . Generally , the follow -
up will be no longer than 6 to 8 weeks following the estim ated delivery  date. Any 
termination of the pregnancy  will be reported regardless of fetal status (presence or 
absence of anomalies) or indication for the procedure. 
Female Participants Who Become Pregnant 
The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study . Information will be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning of a participant ’s pregnancy . The participant will be followed to determine the outcome of the 
pregna ncy. The investigator will collect follow-up information on the participant and the 
neonate, and the information will be forwarded to the sponsor . Generally, follow -up wil l 
not be required for longer than 6 to 8 week s bey ond the estimated delivery date. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170638] -T-01-01 v2.0
While pregnancy itself is not c onsidered to be an adverse event or SAE, an y pregnancy  
complication will be reported as an adverse event or SAE . A spontaneous or elective 
abortion is alway s considered to be an SAE and will be reported as such. Any poststudy  
pregnancy -related SAE consider ed reasonabl y related to the study  interventi on by  [CONTACT_99480] 8.3.4. While the 
investigator is not obligated to actively seek this information in former study participants, 
he or she may learn of an SAE through spontaneous reporting. 
Any female participants who becomes pregnant while participating in the study after 
receiving stud y intervention may  choose to exit the study  after appropriate safet y follow-
up or remain in the stud y for all safety  and efficacy follow -up assessments.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170639] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170640] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170641] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170642] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170643] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170644] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170645] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170646] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170647] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170648] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170649] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170650] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170651] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170652] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170653] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170654] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170655] -T-01-01 v2.0
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170656] -T-01-01 v2.0
11. References
Adler M, Keller JE, Sheridan RE, Deshpande SS. Persistence of botulinum neurotoxin A 
demonstrated by [CONTACT_743621] A and E in rat EDL muscle. Toxicon. 2001;39:233-243.
Barash J, Arnon S. A novel strain of clostridium botulinum that produces type B and t ype H 
botulinum toxins. J Infect Dis ; 2014:209:183-191.
Beer K. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topi[INVESTIGATOR_743600]- to-severe glabellar rhy tids. Dermatol Surg. 2006;32:184-192.
Blitzer A, Brin MF, Keen MS, Aviv JE. Botulinum toxin for the treatment of hy perfunctional 
lines of the face. Arch Otolaryngol Head Neck Surg. 1993;119:1018-1022.
Brin M, Boodhoo T, Pogoda J, Jam es L, Dem os G, Terashima Y. Safet y and tolerability of 
onabotulinumtoxinA in the treatment of facial lines: a meta- analysis of individual patient data 
from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 
2009;61:961-970.
Dona ld S, Elliott M, Gray B, Hornb y F, Lewandowska A, Marlin S, et al. A comparison of 
biological activity of commercially available purified native botulinum neurotoxin serotypes A1 
to F1 in vitro, ex vivo, and in vivo. Pharmacol Res Perspect. 2018;e00446. http://doi. org/10.1002/prp2.446.
Eleopra R, Tugnoli V, Rossetto O, et al. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neuroscience Letters. 1998; 256:135-138.
Farage M, Miller K, Berardesca E, Maibach H. Psy chological and social implications of aging 
skin: normal aging and the effects of cutaneous disease. Textbook of Aging Skin. Springer 
Verlag Berlin Heidelberg. 2010:949 -957.
Finn C, Cox S, Earl M. Social implications of hyperfunctional facial lines. Dermatol Surg. 2003;29:450-455. 
Garcia A, Fulton J. Cosmetic denervation of the muscles of facial expression with botulinum 
toxin: a dose- response study. Dermatol Surg. 1996;22:39 -43.
Keller J, Cai F, Neale E. Uptake of botulinum neurotoxin into cultured neur ons. Biochemistry . 
2004;42:526-532
Keller J. Recovery  from botulinum neurotoxin poisoning in vivo. Neuroscience. 
2006;139:629-637.
Khan JA. Aesthetic surgery : diagnosing and healing the miscues of human facial expression. 
Ophthal Plastic Reconstr Surg. 200 1;17:4 -6.
Koblenzer CS. Psy chologic aspects of aging and the skin. Clin Dermatol. 1996;14:171-177.
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-[ADDRESS_1170657] -T-01-01 v2.0
Le Louarn C, Buthiau D, Buis J. Structural aging: the facial recurve concept. Aesth Plast Surg. 
2007;31:213-218.
McLaughlin JB. Bot ulism ty pe E outbreak associated with eating a beached whale, Alaska. 
Emerg Infect Dis. 2004;10:1685-1687.
Wang J, Meng J, L awrence G, Zurawski T, Sasse A, Bodeker M, et al. Novel chimeras of 
botulinum neurotoxins A and E unveil contributions from the binding, translocation, and 
protease domains to their functional characteristics. J Biol Chem. 2008;283:[ZIP_CODE]-[ZIP_CODE]
Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)Approval Date: 05-Jun-2020 18:45:11 (GMT)
20MAY2021 CSR 2034-201-008 Final 93